Insulin aspart composition (embodiments)
Patent Information
- Application Number
- MYPI2025003341
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-12-04
- Filing Date
- 2023-11-30
- Publication Date
- 2024-06-04
AI Technical Summary
Existing insulin compositions, particularly monomeric analogues like insulin aspart, face challenges with physicochemical stability when exposed to thermal and mechanical stress, leading to aggregation and precipitation, which affects their efficacy and safety in syringe pens and continuous infusion systems.
The addition of surfactants such as poloxamer 188, polysorbate 20, or polysorbate 80 in combination with amino acids like lysine or arginine to insulin aspart compositions improves both chemical and physical stability, reducing the formation of impurities and fibrils.
The improved stability of insulin aspart compositions enhances their performance in syringe pens and infusion systems, maintaining efficacy and safety over extended periods by minimizing aggregation and precipitation, thus ensuring consistent glycemic control.
Smart Images

Figure PI2025003341_DRAWING_001
Abstract
Description
[0001] COMPOSITION OF INSULIN ASPARTA (VARIANTS)
[0002] DESCRIPTION OF THE INVENTION
[0003] Field of technology to which the invention relates
[0004] The invention relates to the field of pharmaceuticals and medicine, namely, to compositions of a fast-acting injectable insulin preparation for reducing blood glucose levels in a subject. More specifically, the present invention relates to compositions containing insulin aspart that have excellent physical and chemical stability, including when exposed to high temperature and / or high mechanical energy.
[0005] State of the art
[0006] Stability of a medicinal product (MP) is a necessary condition for ensuring its therapeutic effect or the absence of new adverse reactions, and it must be ensured both during storage of the MP during its shelf life and during its use. Stable MP compositions are especially necessary for use in delivery devices in which they are exposed to elevated temperatures and / or mechanical loads. For example, stable insulin compositions are necessary for use in syringe pens and continuous infusion systems (using pumps). Insulin compositions are also manufactured, stored and used in vials, which requires their stability throughout their shelf life.
[0007] Injection pens are widely used by patients suffering from diabetes mellitus, the so-called diabetics, since they allow diabetics to effectively manage the course of their disease by timely injection of a medicine with the required dose into the target injection site on the patient's body exactly as prescribed by the attending physician. Such injection pens are quite easy to use, which allows their users to not have any special medical skills and / or any special medical education in order to set the insulin dose to be injected and then inject the specified dose of the medicine into the target injection site on the patient's body. Injection pens usually contain a cartridge containing a certain amount of Jill. The cartridge includes a piston and a mechanism for moving the piston in the cartridge in such a way as to dose the medicine.Injection pens can be reusable or disposable. In reusable pens, the user can replace the used cartridge and return the lead screw of the pen to its original position. In a disposable syringe pen, the cartridge is not replaceable; it is disposed of after the cartridge contents have been used up. When using insulin in cartridges or when carrying spare cartridges, the insulin preparation is stored outside the refrigerator until the cartridge is completely used up (usually for at least 2 weeks) or until the manufacturer's recommended shelf life of the used or carried cartridge has expired - no more than 1 month. Since insulin pens are often stored in clothing pockets at a temperature close to body temperature, the insulin compositions used in such syringe pens are subject to physical and temperature stress, as a result of which they have limited stability.
[0008] In the case of continuous infusion systems, the insulin solution to be administered by means of an infusion device is stored in a reservoir, such as a syringe, a synthetic polymer chamber, a metal container, etc. The reservoir and a pump mechanism operatively connected thereto are attached to the patient's body or implanted in the patient's body. Insulin is pumped from the reservoir through small-diameter catheters subcutaneously, intravenously or intraperitoneally by a pump, whereby the insulin composition is exposed to body temperature and movement, as well as to the pumping movement of the pump and, thus, to a high thermomechanical load.
[0009] Existing insulin compositions, mostly its monomeric analogues, do not provide sufficient physicochemical stability in syringe pens and continuous infusion systems. The main problem that arises when administering insulin using syringe pens and infusion systems is the tendency of insulin solutions to form aggregates, fibrils or insulin precipitates over time [1 J. Aggregates and precipitates lead to damage to catheter or pump components, and in the case of syringe pens to damage to needles, which contributes to the cessation of insulin flow into the patient's body and poor glycemic control.
[0010] The aggregation and precipitation of insulin in solution is influenced by many factors, the main ones being:
[0011] ( ) elevated temperature, for example, 25~37°C, as opposed to normal (2-8°C) storage conditions [2J;
[0012] (b) mechanical energy caused by body movement or movement of pump piston mechanisms [3]; (c) prolonged interaction of insulin molecules with hydrophobic surfaces such as air interfaces and plastic or metal pump components [4,5].
[0013] Insulin is a peptide hormone that regulates blood glucose levels in mammals by initiating a signaling cascade that accelerates glucose uptake and glycogen production upon binding to the insulin receptor. When insulin production is impaired, blood glucose levels increase (chronic hyperglycemia), which is the primary diagnostic feature of type 1 diabetes (T1D). However, when signal transmission from insulin receptors is impaired, even if the hormone is produced in sufficient quantities, type 2 diabetes (T2D) develops due to decreased tissue sensitivity to insulin (insulin resistance). The effectiveness of insulin in the treatment of diabetes mellitus, due to the ability of this hormone to lower blood glucose levels, has been proven over decades of its use in medical practice.However, the search for new approaches to the treatment of diabetes mellitus remains relevant due to the increasing number of cases of the disease and the need to take into account the individual characteristics and preferences of patients [6].
[0014] The development of rapid-acting and ultra-rapid-acting insulin analogues with a more rapid onset of action and shorter duration of action has been a significant advance in the treatment of type 1 and type 2 diabetes. In neutral solution at pharmaceutical concentrations, insulin and its analogues exist as stabilized zinc-containing hexamers, which consist of three identical dimeric units. The delay in insulin action is largely due to the time it takes for the hexamers to dissociate into absorbable monomers and dimers [7,8]. The first class of rapid-acting insulins (e.g., insulin lispro and aspart) were developed based on amino acid mutations in the human insulin sequence, which resulted in weakened self-association of insulin oligomers.For example, the substitution of the amino acid proline at position B28 with aspartic acid in insulin aspart reduces the tendency of molecules to form hexamers, which is observed in a solution of soluble human insulin. In this regard, insulin aspart is absorbed much faster from the subcutaneous fat compared to soluble human insulin and is widely used for postprandial control of blood glucose levels in patients with diabetes mellitus [9]. It is known that fast-acting insulin analogues, which are in monomeric or dimeric form, have reduced physicochemical stability compared to hexamers
[0010] , especially under thermal and mechanical stress, in particular they form high-molecular impurities, and an increased tendency to aggregation (fibrillation), which is manifested in the form of turbidity and sediment.High-molecular impurities (dimers, trimers, polymers) and aggregates not only reduce the administered insulin dose, but can also provoke irritation or immune reactions in the patient. In addition, insoluble aggregates can clog and damage needles, cannulas and pump hoses. To ensure the quality of the insulin composition, it is necessary to avoid the formation of polymers and aggregates.
[0015] There are insulin aspart medicinal products on the market (for example, NovoRapid (Novo Nordisk A / S), RinFast (GEROPHARM LLC). It has been shown that overall glycemic control can be improved by introducing the excipient nicotinamide into the composition of the product, which is capable of accelerating the absorption of insulin aspart, compared to insulin aspart preparations without nicotinamide. In particular, it has been shown that Fiasp (containing nicotinamide) compared to NovoRapid (not containing nicotinamide) provided improved overall glycemic control and better postprandial glycemic control without increasing the overall risk of severe or confirmed hypoglycemia in patients with type 1 and type 2 diabetes. The pharmacokinetic characteristics of the rapid-acting insulin aspart Fiasp can better reproduce the rapid endogenous secretion of prandial insulin and, thus, improve postprandial glycemic control compared with insulin aspart
[0011] .
[0016] Nicotinamide has the ability to accelerate the absorption of insulin (WO 91 / 09617), including insulin aspart (WO / 9610417), but has a negative effect on chemical stability - increases the content of impurities (RU2533217). The chemical stability of the composition of the medicinal product (Jill) "FIASP" is increased by introducing arginine into the composition, which is reflected in a decrease in the content of dimers and polymers, deamidated insulins during storage (RU2533217). Jill "FIASP" is the closest analogue of the present invention.
[0017] In a report of a small (n = 37) 6-week study of the susceptibility of infusion sets to clogging and malfunction, no cases of infusion set clogging were noted with either FIASP (25 subjects) or insulin aspart (12 subjects). However, unexplained hyperglycemia and premature infusion set changes were more common with FIASP than with insulin aspart
[0012] .
[0018] Patent RU2533217 shows (example 2) that adding arginine to compositions containing insulin aspart with nicotinamide reduces the amount of impurities formed, especially high molecular weight protein and deamidated forms, but at the same time the physical stability, measured as the delay time in the analysis with thioflavin T, decreases; with an increase in the concentration of arginine, the physical stability decreases even more.
[0019] Our study of the tendency to form fibrils in the thioflavin T assay also showed that FIASP is more prone to fibrillation compared to NovoRapid.
[0020] Thus, at present, there remains a need for insulin compositions with increased stability when using syringe pens, as well as during continuous infusion using pumps -- from several days to several months. Improving the stability of insulin compositions when used in vials is also useful. The above-mentioned technical problem is especially relevant for compositions of monomeric insulin analogues, including insulin aspart, which are less stable than hexameric forms of insulin, as well as for compositions containing nicotinic acid compounds that can accelerate the absorption of insulin, but at the same time negatively affect the chemical stability of insulin.
[0021] ESSENCE OF THE INVENTION
[0022] The authors of the present invention have unexpectedly discovered that the addition of surfactants such as poloxamer 188, polysorbate 20, polysorbate 80 or combinations thereof in combination with one or more amino acids selected from lysine, arginine and / or their salts to compositions containing insulin aspart and nicotinamide improves both the chemical and physical stability of insulin aspart in comparison with the analogue.
[0023] The present invention relates to compositions for lowering blood glucose levels in a subject, comprising insulin aspart (B28Asp), a nicotinic acid compound, one or more amino acids or salts thereof selected from lysine, arginine or their salts, and a surfactant.
[0024] In preferred embodiments, the present invention relates to compositions for lowering blood glucose levels in a subject comprising INSULIN aspart, a nicotinic acid compound, an amino acid selected from lysine, arginine and / or a salt thereof and / or a combination thereof, and a surfactant selected from poloxamer 188, polysorbate 20, polysorbate 80 and / or a combination thereof.
[0025] The concentration of insulin aspart in the compositions of the invention is from about 0.2 mM to 2.0 mM (from about 33 U / ml to about 333 U / ml), preferably from about 0.3 mM to 1.2 mM (from about 50 U / ml to about 200 U / ml), even more preferably 0.6 mM (100 U / ml).
[0026] In one embodiment of the present invention, the compositions have a pH of from 6.5 to 8.5, preferably from 6.6 to 7.4, even more preferably the pH is 7.
[0027] The compositions of the invention comprise a nicotinic acid compound selected from nicotinamide (niacinamide), nicotinic acid (niacin) and / or a salt thereof and / or any combination thereof. The concentration of nicotinamide or another nicotinic acid compound in the compositions of the invention is from about 1 mM to about 200 mM. A preferred nicotinic acid compound is nicotinamide.
[0028] The concentrations of lysine and / or its salt and arginine and / or its salt or the total concentration of lysine and / or its salt in combination with arginine and / or its salt are from about 1 mM to about 100 mM.
[0029] In compositions containing a combination of lysine and / or its salt and arginine and / or its salt, the molar ratio of amino acids is from 4000:1 to 1:4000, respectively, said range including each integer ratio, such as 100:1, 99:1, 98:1, etc. In one preferred embodiment, the molar ratio of lysine to arginine is 1:1, 4:5, 5:4, 6:4; 5:2 or 2:5.
[0030] The compositions of the invention may additionally contain protease inhibitor(s), metal ions, buffer systems, pH regulators, preservative(s), isotonic agent(s), chelating agent(s), stabilizers and surfactants.
[0031] In one embodiment of the invention, the compositions of the invention are aqueous compositions, i.e. compositions containing water and are solutions or suspensions.
[0032] The compositions of the present invention can be used for the treatment or prevention of hyperglycemia, type 2 diabetes mellitus, impaired glucose tolerance, type 1 diabetes mellitus.
[0033] In one preferred embodiment, the compositions of the invention are administered parenterally. Parenteral administration may be performed by subcutaneous, intramuscular, intraperitoneal or intravenous injection using a syringe, possibly a syringe pen. Alternatively, parenteral administration may be performed using an infusion pump.
[0034] Thus, the present invention also relates to injectable insulin preparations containing the compositions of the present invention.
[0035] The compositions of the invention have shown improvement in both chemical and physical stability compared to the analogue of the invention, which is useful for consumers, especially when using syringe pens or insulin pumps.
[0036] TERMS AND DEFINITIONS
[0037] The term "human insulin" as used in this document refers to a human hormone whose structure and properties are well known. Insulin is a polypeptide of 51 amino acids, which is divided into 2 amino acid chains: chain A, consisting of 21 amino acids, and chain B, consisting of 30 amino acids. The chains are linked together by 2 disulfide bridges. Insulin preparations have been used to treat diabetes mellitus for many years, and recently not only insulins of natural origin have been used, but also insulin derivatives and analogs.
[0038] An "insulin analog" as referred to herein is a polypeptide derived from the primary structure of natural insulin, such as human insulin, by mutation. One or more mutations are obtained by deleting and / or replacing at least one amino acid residue occurring in natural insulin and / or by adding at least one amino acid residue. Mutations in the insulin molecule are designated by indicating the chain (A or B), position, and three-letter code for the amino acid replacing the native amino acid.
[0039] The term "rapid-acting insulin" or "short-acting insulin" refers to insulin analogues and / or insulin derivatives that have an onset of action within 5-15 minutes and a duration of action of 3-4 hours. Examples of rapid-acting insulins include, but are not limited to, insulin aspart, insulin lispro, and insulin glulisine.
[0040] The terms "monomeric human insulin analogue" and "monomeric insulin analogue" are well known in the art and generally refer to rapidly acting analogues of human insulin. Examples of these include insulin lispro (Humalog®), insulin aspart (NovoRapid®) and insulin glulisine (Apidra®). The molecular structure of insulin lispro is identical to that of human insulin except for positions 28 and 29 of the B-chain of the molecule, where lysine and proline are arranged in the reverse order (human insulin: B28ProB29Lys, lispro: B28LysB29Pro). The reverse arrangement of lysine and proline allows the lispro molecule to dissociate twice as fast. In the structure of insulin aspart (B28Asp), the amino acid residue Pro at position 28 of the B-chain of human insulin is replaced by Asp, which reduces the tendency of the molecules to form hexamers observed in human insulin solution.In the structure of insulin glulisine (3BLys29BGlu), the amino acid residue asparagine in the 3rd position of the B-chain of the human insulin molecule is replaced by lysine, and lysine in the 29th position of the B-chain is replaced by glutamine, which contributes to the stability of this drug in solution in the form of monomers and dimers.
[0041] The content of human insulin B28Asp in the solution may be in the range of about 0.2 mM to about 2.0 mM (about 33 to about 333 international units (IU) / mL), preferably in the range of about 0.3 mM to about 1.2 mM (about 50 to about 200 IU / mL), particularly preferably at a concentration of 0.6 mM (IU / mL), in injection preparations. However, for other parenteral administration purposes, the content of the insulin compound may be higher.
[0042] In this context, the unit "IU" corresponds to 6 nmol.
[0043] The term "insulin aspart composition" as used herein means a product comprising insulin aspart, a nicotinic acid compound selected from nicotinamide (niacinamide), nicotinic acid (niacin) and / or a salt thereof and / or any combination thereof, an amino acid selected from lysine, arginine and / or a salt thereof and / or a combination thereof, a surfactant selected from poloxamer 188, polysorbate 20, polysorbate 80 or a combination thereof, which may also contain other excipients such as preservatives, chelating agents, isotonic agents, fillers, stabilizers, antioxidants, polymers and surfactants other than the above, metal ions, oil carriers and proteins (e.g. human serum albumin, gelatin or proteins), pH regulators, wherein the insulin aspart composition can be used to treat, prevent or reduce the severity of a disease or disorder by administering it to a person.Thus, the composition of the present invention may be referred to as a "pharmaceutical composition" or.
[0044] "pharmaceutical preparation". The terms "protein preparation", "protein composition" and "protein" may be used interchangeably within the framework of the present invention and mean any medicinal product containing as an active substance a molecule consisting of polypeptide chains consisting of amino acid residues linearly linked by a peptide bond, alone or in combination with other compounds. An insulin composition or insulin, for example, are special cases and are covered by these terms.
[0045] The terms arginine and lysine refer to amino acids and include the D- and L-enantiomers, as well as mixtures thereof. The term also includes any pharmacologically acceptable salts of arginine and lysine. Arginine and lysine readily form salts, such as hydrochlorides.
[0046] The term "surfactant" as used herein refers to any molecule or ion that consists of a water-soluble (hydrophilic) portion, a head, and a fat-soluble (lipophilic) segment. Surfactants concentrate preferentially at the interface with the hydrophilic portion facing the water (hydrophilic phase) and the lipophilic portion facing the oil or hydrophobic phase (i.e., glass, air, oil, etc.). Surfactants reduce the surface tension of a liquid. They are also known as amphipathic compounds. The term "detergent" is generally synonymous with the term "surfactant." The use of surfactants in pharmaceutical formulations is well known to those skilled in the art. These include, for example, polysorbate 20, polysorbate 80, poloxamer 188, etc. These substances are described as excipients in current pharmacopoeias (USP, EP).
[0047] The term "nicotinic acid compound" includes nicotinamide (niacinamide), nicotinic acid (niacin) and / or salts thereof and / or any combination thereof.
[0048] The buffer may be selected from the group consisting of sodium acetate, sodium carbonate, citrate, sodium dihydrogen phosphate, sodium hydrogen phosphate, sodium phosphate, as well as tris(hydroxymethyl)aminomethane, bicine, tricine, malic acid, succinate, maleic acid, fumaric acid, tartaric acid, aspartic acid, or mixtures thereof, but not limited to them. Each of these specific buffers or each of their combinations is an alternative embodiment of the invention.
[0049] The compositions of the present invention may also contain other ingredients commonly used in insulin preparations, such as zinc complexing agents. Isotonic agents such as glycerol, mannitol, sodium chloride, dextrose, etc. may also be present in the compositions of the present invention. An isotonic agent is a physiologically acceptable compound that imparts suitable tonicity to the composition in order to prevent diffusion of water through cell membranes in contact with the pharmaceutical composition.
[0050] The compositions of the present invention may contain a pharmaceutically acceptable preservative. The preservative present in the insulin preparation of the present invention may be phenol, m-cresol, methylparaben, etc.
[0051] The compositions of the present invention may also contain a chelating agent. The use of chelating agents in pharmaceutical preparations is well known to those skilled in the art.
[0052] The compositions of the present invention may also contain a stabilizer. The term "stabilizer" as used herein refers to chemicals added to pharmaceutical preparations containing a polypeptide to stabilize it, i.e. to increase the shelf life and / or time of use of such preparations.
[0053] As used herein, the term "stability" refers to the chemical and physical stability of the monomeric insulin analog compositions.
[0054] Physical instability of a protein composition (protein preparation) and / or protein may be caused by aggregation of protein molecules to form higher order polymers or even precipitates. Physical denaturation of insulin is known as fibrillation. In the fibrillar state, the elongated peptide chains are arranged parallel or antiparallel and hydrogen bonded to each other, forming the so-called P-structure or P-pleated sheets. Fibrils usually represent the lowest energy state of the protein, and regeneration of the protein from this state to the native state of correctly folded protein is possible only in a highly alkaline environment. Insulin fibrils appear as gels or precipitates. Factors that promote an increase in the rate of fibril formation include exposure to thermomechanical stress and / or interaction with phase boundaries and hydrophobic surfaces. Fibril formation is believed to occur due to insulin monomerization.Monomeric insulin analogues that readily dissociate from the hexameric unit to the monomeric form are more prone to fibril formation than human insulin. Physical stability can be assessed by methods well known in the art, such as measuring turbidity (optical density). Turbidity results from aggregation or precipitation of proteins or complexes in the formulations.
[0055] The physical stability of aqueous protein preparations can also be assessed using a spectroscopic agent or probe of the protein conformational state. The probe is preferably a small molecule that preferentially binds to non-native conformers of the protein. One example of a small molecule spectroscopic probe of protein structure is thioflavin T. Thioflavin T is a fluorescent dye that is widely used to detect amyloid fibrils. In the presence of fibrils and possibly also other protein conformations, thioflavin T produces a new excitation maximum at about 445 nm and enhances the emission at about 485 nm when bound to the fibrillar form of the protein. Unbound thioflavin T is essentially non-fluorescent at these wavelengths.
[0056] The term "chemical stability" of a protein composition (protein preparation) and / or protein, as used in the present description of the invention, refers to changes in the covalent structure of the protein, leading to the formation of chemical degradation products with potentially lower biological activity and / or potentially enhanced immunogenic properties compared to the native structure of the protein. Different chemical degradation products can be formed depending on the type and nature of the native protein and the external factors to which the protein is exposed. An increase in the amount of chemical degradation products is often observed during storage and use of the protein preparation.Most proteins are prone to deamidation, other degradation pathways involve the formation of high molecular weight products in which two or more protein molecules are covalently linked to each other through transamidation and / or disulfide interactions, resulting in the formation of covalently linked dimeric, oligomeric and polymeric degradation products
[0013] . Another option for chemical degradation is oxidation (e.g. of methionine residues). The chemical stability of a protein preparation and / or protein can be assessed by measuring the amount of chemical degradation products at various time points after exposure to various environmental conditions (the formation of degradation products can often be accelerated, e.g. by increasing the temperature).The amount of each individual degradation product is often determined by separating the degradation products based on molecular size and / or charge using various chromatographic techniques (e.g., size exclusion liquid chromatography (SEC-HPLC) and / or reversed-phase high-performance liquid chromatography (RP-HPLC)). Since high molecular weight protein products are potentially immunogenic and biologically inactive, high molecular weight protein levels should be low.
[0057] A “stable composition” is a composition in which the degree of protein aggregation and the content of impurities are within the normal range and do not exceed it over time.
[0058] In one embodiment, the compositions of the invention are aqueous compositions, i.e. compositions containing water and are a solution or suspension.
[0059] The term "aqueous composition" refers to a composition containing water. The terms "aqueous solution" and "aqueous suspension" refer, respectively, to a solution or suspension containing water. Aqueous suspensions may contain the active compounds in admixture with excipients suitable for the manufacture of aqueous suspensions.
[0060] EXAMPLES
[0061] Example 1. Preparation of compositions 1 - 9.
[0062] In one embodiment, the pharmaceutical compositions of the present invention are prepared in the form of aqueous solutions. Table 1 shows the qualitative and quantitative composition of some of the prepared compositions, the composition of composition 1 corresponds to the composition of the closest analogue of the invention. Compositions of the invention include, but are not limited to, compositions 2, 3, 6-9, shown in Table 1.
[0063] The method for producing the compositions comprises: a) preparing a solution of insulin aspart by dissolving it in water or buffer; b) preparing a solution of zinc salt by dissolving it in water or buffer; c) preparing a solution of preservatives (phenolic compounds) by dissolving them in water or buffer; d) preparing a solution of an isotonic agent by dissolving it in water or buffer; d) preparing a solution of nicotinamide and / or another nicotinic acid compound by dissolving in water or buffer; e) preparing a solution of surfactant by dissolving a surfactant in water or buffer; g) preparing a solution of lysine and / or arginine by dissolving amino acids and / or their salts in water or buffer; h) mixing solution a) and solutions b), c), d), e), f), g) in accordance with the composition of the compositions given in Table 1; i) bringing the pH of mixture h) to a value of 6.6-7.4, followed by sterilizing filtration. j) aseptic filling of cartridges with prepared compositions.The compositions of the invention can be prepared by any other method.
[0064] Table 1. Qualitative and quantitative composition of the compositions according to the invention
[0065] Example 2. Analysis of physical and chemical stability of compositions
[0066] The chemical stability was determined for compositions 1-9, obtained according to example 1, after thermostatting the aseptically filled cartridges at a temperature of 40°C for 1 and 2 weeks.
[0067] Determination of insulin aspart-related impurities was carried out by HPLC with UV detection in combination with the “Quantitative Determination” indicator on a column filled with octadecyl silica gel with a particle size of 5 μm and a pore size of 300 A with a mobile phase flow rate of 1.0 ml / min and a wavelength of 214 nm.
[0068] Elution was carried out with a mobile phase in gradient mode, consisting of the following components:
[0069] Mobile phase A (MP A): 10% (w / V) acetonitrile, buffer solution pH 3.4 (1.4% (w / V) anhydrous sodium sulfate, 0.13% (V / V) concentrated phosphoric acid, 2 M sodium hydroxide to pH 3.4 ± 0.05).
[0070] Mobile phase B (MP B): 50% (w / V) acetonitrile.
[0071] The amount of impurity B28IsoAsp, deamidated (B3iso, A21Asp, B3Asp) and other related impurities was determined by the method of internal normalization by the absorption area of the corresponding peaks, measured as a percentage of the sum of the areas of the peaks eluted after nicotinamide and preservatives.
[0072] The amount of high-molecular protein (HMP) was determined by size-exclusion liquid chromatography on a column filled with hydrophilic silica gel for chromatography with a particle size of 10 μm and a pore diameter of 125 A. A mixture of acetonitrile: glacial acetic acid: 0.1% arginine solution (20: 15: 65) (V / V / V) was used as an eluent. Elution was carried out at a flow rate of 0.5 ml / min at a detection wavelength of 276 nm.
[0073] The content of VMB was determined by the method of internal normalization based on the sum of the absorption areas of all peaks with retention times shorter than that of the insulin aspart monomer peak. Peaks with retention times longer than that of the insulin aspart monomer peak (nicotinamide and preservatives) were not taken into account in the calculation.
[0074] To assess the physical stability of the protein compositions, an analysis was performed for the tendency to form fibrils using Thioflavin-T (ThT). The selected method is described in the literature, for example, in patent RU2533217. The tendency to form fibrils was determined for compositions 1 - 9 given in Example 1, as well as for the finished form of the original medicinal product "Fiasp". The composition of the medicinal product "Fiasp" was reproduced in composition 1. The analysis was performed immediately after the preparation of the compositions.
[0075] Preparation of solutions
[0076] Stock solution of thioflavin
[0077] Take an exact weighed portion of the dry Thioflavin T reagent, dissolve in methanol to a thioflavin concentration of 1 mg / ml (which corresponds to 3.14 mM). Mix the solution thoroughly on a vortex, store protected from light at a temperature of + 2 - 8 °C for up to 6 months.
[0078] Working solution of thioflavin
[0079] Prepare a working solution with a thioflavin concentration of 200 μM in purified water. The volume of the stock solution to purified water is calculated in the proportion of 1:14.7. Use freshly prepared.
[0080] Aliquots of 100 μl of samples in triplicates are placed in a black 96-well plate; purified water is used as a control sample. 10 μl of the working solution of thioflavin were added to all wells. When filling the plate, the outer wells are avoided (see Fig. 1). The plate is sealed with transparent film and placed in a CLARIOstar multimodule plate reader (B MG, Germany). The fluorescent signal is detected every 20 minutes for 12 hours at a wavelength of 445 / 485 nm. Between readings, the plate is stirred at 700 rpm. Stirring and detection are carried out at a temperature of 37 °C.
[0081] Based on the measurement results, graphs of the signal dependence in relative fluorescence units on time in hours are constructed for each sample. A 4-parameter dependence is used for analysis.
[0082] The graph is used to determine T1 / 2max - the time during which half of the analyzed sample aggregates. If the graph is obtained in the form of a straight line at the zero value level, the sample is considered not prone to aggregation; in other cases, the degree of proneness to aggregation is estimated by T1 / 2max.
[0083] Along with T1 / 2max, the ThT fluorescence curve visually determines the delay time as the time point at which Th T fluorescence differs from the background level. Table 2. Data on the physical and chemical stability of insulin compositions 1-9 from Table 1 (example 1)
[0084] * Original LP "Fiasp"
[0085] ** "not detected", absence of fibrils
[0086] Based on the study of the chemical and physical stability of insulin aspart compositions prepared using both a phosphate buffer and a tris buffer, it was unexpectedly discovered that when adding amino acids selected from lysine, arginine and / or their salts and / or their combinations in combination with surfactants such as poloxamer 188, polysorbate 20 and polysorbate 80 or their combinations, the amount of impurities after 2 weeks of storage at 40°C in the compositions of the invention (in compositions 2, 3, 6-9) is significantly and reliably less than in the analogue, another fundamental advantage of the compositions of the invention is an increase in physical stability, namely the absence of a tendency to fibrillation. For the compositions of the invention, the appearance of fibrils was not noted (ND), however, with an increase in the concentration of amino acids in them above 100 mM, physical stability worsens, a tendency to fibrillation appears.
[0087] Compositions 1-9, prepared according to the method described in Example 1, were tested for physical stability in an acceleration test. Three 3 / 16 inch (4.7625 mm) diameter Teflon beads were placed in 2 ml glass HPLC vials. The vials were completely filled with samples of the compositions to be tested. The closed vials were continuously shaken at 40 Hz (average linear acceleration of 20 * g) with an amplitude of 12 mm at a temperature of 37 °C, thus subjecting the prepared compositions to a relatively high level of thermal and mechanical stress, i.e., conditions that favor physical instability. The vials were placed on a shaker so that they were oriented in their long dimension (from top to bottom) parallel to the direction of linear acceleration, in other words, they were laid on their sides on the surface of the shaker.For other insulin formulations, it has been shown that increased stability under the acceleration conditions described correlates with significantly improved stability of the formulations in use. The turbidity (optical density at 450 nm) of the test and control samples is measured periodically with a spectrophotometer. The control samples are prepared in the same manner as the test samples, but are stored at 2 - 8° C without shaking. The resulting optical density is calculated by subtracting the optical density of the control sample from the optical density of the test sample. Table 3 shows the average resulting optical density and standard deviation values for a number of samples.
[0088] Table 3. Effect of composition of the compositions and exposure time under mechanical energy at 37°C on turbidity (optical density at 450 nm)
[0089]
[0090] Under the described experimental conditions, the turbidity of the finished compositions not containing a combination of surfactant and amino acid (composition 1) or not containing only surfactant (composition 5) reaches high values, which become unacceptable by 24 hours for composition 1 or by 72 hours for composition 5, respectively. The optical density of all compositions containing surfactant and amino acid remains practically the same as that of the control samples during 336 hours of the experiment. The optical density of composition 4 also remains practically the same as that of the control samples, but the content of chemical degradation impurities in this composition is significantly higher than in the samples containing a combination of surfactant and amino acid.
[0091] Based on observations made using finished forms of other insulins, it can be assumed that such an unexpected and significantly increased stability of insulin compositions containing a combination of surfactants and amino acid in the acceleration test will be transferred to the stability in their practical use over a period of more than 336 hours, since in the acceleration test carried out the compositions are subjected to a stronger effect than when using compositions in syringe pens and infusion systems. References: Lougheed WD, Woulfe-Flanagan H., Clement JR, Albisser AM Insulin aggregation in artificial delivery systems. Diabetologia. 1980, 19(1), 1-9. doi:10.1007 / bf00258302 Fisher H., Porter PB Pharmaceutical. Pharmacology. 1980, 33:203-206. Irsigler K., Kritz H. Long-Term Continuous Intravenous Insulin Therapy with a Portable
[0092] Insulin Dosage-regulating Apparatus. Diabetes. 1979, 28(3): 196—
[0093] 203. doi:10.2337 / diab.28.3.196 Weisenfeld S., Podolsky S. Goldsmith, L. Ziff L. Adsorption of Insulin to Infusion Bottles and Tubing. Diabetes. 1968, 17(12): 766-771. doi:10.2337 / diab.17.12.766 Browe et al. European Journal of Biochemistry . 1973, 33 :233. Selivanova O. M., Grishin S. Yu., Glyakina A. V. et al. Analysis of insulin analogs and strategy for their further development. Advances in Biological Chemistry . 2018, 58: 313-346. Brange J., Owens DR, Kang S., Volund A. Monomeric Insulins and Their Experimental and Clinical Implications. Diabetes Care. 1990, 13(9), 923-
[0094] 954. doi:10.2337 / diacare.l 3.9.923 Schlein M. Insulin Formulation Characterization - the Thioflavin T Assays. AAPS Journal. 2017, 19(2): 397 - 408. Instructions for use of the medicinal product for medical use "Fiasp". URL: http: / / grls.rosminzdrav.ru (accessed 30.08.22).. Brange J. Stability of Insulin. Kluwer Academic Publisher. 1994, 18-23. . Paquot N., Scheen AJ Faster aspart insulin (FIASP®). Revue Medicale de Liege. 2018; 73 (4): 211-215. . Muchmore DB Pump Users Clamor for Faster Insulin: Is Fast-Acting Insulin Aspart Ready for Them? Journal of Diabetes Science and Technology. 2018; 12(1): 152- 154. doi:10.1177 / 1932296817750166. Ahem TJ, Manning MC Stability of Protein Pharmaceuticals. Plenum Press. New York. 1992.
Claims
CLAUSES OF THE INVENTION 1. A composition for lowering blood glucose levels in a subject, comprising insulin aspart (B28Asp), a nicotinic acid compound, one or more amino acids or salts thereof selected from lysine, arginine or their salts, and a surfactant.
2. The composition according to claim 1, which contains as a surfactant one or more surfactants selected from poloxamer 188, polysorbate 20 and polysorbate 80.
3. The composition of claim 1, wherein insulin aspart (B28Asp) is present in an amount of from about 0.2 mM (33 U / ml) to about 2 mM (333 U / ml).
4. The composition of claim 1, wherein insulin aspart is present in an amount of from about 0.3 mM (50 U / ml) to about 1.2 mM (200 U / ml).
5. The composition of claim 1, wherein the nicotinic acid compound is nicotinamide.
6. The composition of claim 1, comprising from about 1 mM to about 200 mM nicotinamide.
7. The composition of claim 1, comprising from about 1 mM to about 100 mM lysine or a salt thereof.
8. The composition of claim 1, comprising from about 1 mM to about 100 mM arginine or a salt thereof.
9. The composition of claim 1, comprising from about 1 mM to about 100 mM of a combination of arginine or a salt thereof with lysine or a salt thereof.
10. The composition of claim 1, comprising one or more surfactants selected from poloxamer 188, polysorbate 20, and polysorbate 80 at a concentration of from about 0.001 to 0.05% w / v.
11. The composition according to claim 1, further containing a metal ion, preservative(s), isotonic agent(s) and stabilizer(s), buffer(s) and acidity regulators.
12. A composition according to any one of paragraphs 1-11 for use in the treatment or prevention of hyperglycemia, type 2 diabetes mellitus, impaired glucose tolerance, type 1 diabetes mellitus.
13. An injectable insulin preparation for lowering blood glucose levels in a subject, comprising a composition according to any one of paragraphs 1-11.
